Ibudilast

Generic Name: Ibudilast

Drug Type: Small Molecule

Chemical Formula: C_₁₄H_₁₈N_₂O

CAS Number: 50847-11-5

Unique Ingredient Identifier: M0TTH61XC5

Overview

Ibudilast is an anti-inflammatory and neuroprotective oral agent which shows an excellent safety profile at 60 mg/day and provides significantly prolonged time-to-first relapse and attenuated brain volume shrinkage in patients with relapsing-remitting (RR) and/or secondary progressive (SP) multiple sclerosis (MS). Ibudilast is currently in development in the U.S. (codes: AV-411 or MN-166), but is approved for use as an antiinflammatory in Japan.

Background

Indication

For the treatment of multiple sclerosis, asthma, and cerebrovascular disease.

Associated Conditions

No associated conditions information available.

First Patient Enrolled in NIH-Funded Expanded Access Program for MN-166 in Advanced ALS

2 months ago

MediciNova has enrolled the first patient in an NIH-funded Expanded Access Program trial evaluating MN-166 (ibudilast) in approximately 200 ALS patients who are ineligible for the ongoing Phase 2/3 COMBAT-ALS trial.

MediciNova's Ibudilast Shows Promise in ALS Trial: Interim Analysis Reveals Strong Correlations

6 months ago

MediciNova's COMBAT-ALS Phase 2/3 trial of MN-166 (ibudilast) in ALS shows positive correlations between 6-month and 12-month data for key metrics.

Ibudilast Expanded Access Program for ALS Patients Managed by Widetrial

6 months ago

Widetrial will manage the physician network for an expanded access program (EAP) providing ibudilast (MN-166) to ALS patients ineligible for clinical trials.

MediciNova's Ibudilast (MN-166) Shows Promise in ALS Treatment: Phase 2/3 Trial Update

8 months ago

MediciNova presented an update on its Phase 2/3 COMBAT-ALS trial of MN-166 (ibudilast) for amyotrophic lateral sclerosis (ALS) at the 2024 Annual NEALS Meeting.

MediciNova's Ibudilast (MN-166) Shows Promise in COMBAT-ALS Trial: Interim Analysis to be Presented at International Symposium

9 months ago

MediciNova's MN-166 (ibudilast) abstract, detailing the COMBAT-ALS trial for ALS treatment, has been accepted for a poster presentation.

Drug Development Updates